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LGI Proteins and Epilepsy in Human and Animals
A. Pakozdy, M. Patzl, L. Zimmermann, T.S. Jokinen, U. Glantschnigg, A. Kelemen, and D. Hasegawa
Leucine-rich glioma-inactivated (LGI) protein was ﬁrst thought to have a suppressor eﬀect in the formation of some can-
cers. Developments in physiology and medicine made it possible to characterize the function of the LGI protein family and
its crucial role in diﬀerent conditions more precisely. These proteins play an important role in synaptic transmission, and dys-
function may cause hyperexcitability. Genetic mutation of LGI1was conﬁrmed to be the cause of autosomal dominant lateral
temporal lobe epilepsy in humans. The LGI2 mutation was identiﬁed in benign familial juvenile epilepsy in Lagotto
Romagnolo (LR) dogs. Cats with familial spontaneous temporal lobe epilepsy have been reported, and the etiology might be
associated with LGI protein family dysfunction. In addition, an autoimmune reaction against LGI1 was detected in humans
and cats with limbic encephalitis. These advances prompted a review of LGI protein function and its role in diﬀerent seizure
disorders.
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As a result of microbiological and genetic develop-ments in recent decades, the etiology of diﬀerent
neurological disorders has become more clear. This pro-
gress also has improved our understanding of the various
forms of epilepsy. The majority of congenital epilepsies
are caused by mutations in genes that encode ion chan-
nels.1 The ﬁrst epilepsy of humans not caused by an ion
subunit-coding mutation, but with a conﬁrmed genetic
background, was autosomal dominant lateral temporal
lobe epilepsy (ADLTE).2 The condition is caused by a
mutation in a gene that codes a neuroprotein called
LGI1. Leucine-rich glioma-inactivated protein (LGI1)
was so named because it has a suppressor eﬀect on glio-
blastomas.3 There are 4 diﬀerent proteins in the LGI
family, and LGI1 was the ﬁrst identiﬁed and best investi-
gated. Today, more than 30 diﬀerent mutations are
reported with some diﬀerences within the epileptic pheno-
type.4 The proteins LGI2, 3, and 4 also play roles in the
central and peripheral nervous system.5
The aim of our review was to summarize research on
LGI proteins because these proteins have become rele-
vant in veterinary medicine in recent years mainly in
the ﬁeld of epilepsy.
LGI Function
LGI1 is a neuronally secreted protein that contains 3
leucine-rich repeats (LRR) in the N-terminal region3
and epitempin (EPTP) repeats in the carboxyl half of
the protein6 as protein–protein interaction domains.
Epitempin repeats were only found in the LGI1 gene.7
The protein LGI1 is multifunctional. It binds to the
presynaptic voltage-gated potassium channel Kv1.1 (Kv
From the University Clinic of Small Animals, University of
Veterinary Medicine, Vienna, Austria (Pakozdy, Glantschnigg);
Institute of Immunology, University of Veterinary Medicine, Vienna,
Austria (Patzl); Unit of Physiology and Biophysics, University of
Veterinary Medicine, Vienna, Austria(Zimmermann); Department
of Equine and Small Animal Medicine, University of Helsinki,
Helsinki, Finland (Jokinen); Epilepsy Center, National Institute of
Clinical Neurosciences, Budapest, Hungary (Kelemen); Department
of Clinical Veterinary Medicine, Nippon Veterinary and Life
Science University, Musashinoshi, Tokyo, Japan (Hasegawa).
Corresponding author: A. Pakozdy, Clinic for Small Animals
Internal Medicine, Veterinaerplatz 1, 1210 Vienna, Austria; e-mail:
akos.pakozdy@vetmeduni.ac.at
Submitted November 25, 2014; Revised March 23, 2015;
Accepted April 11, 2015.
© 2015 The Authors. Journal of Veterinary Internal Medicine pub-
lished by Wiley Periodicals, Inc. on behalf of the American College of
Veterinary Internal Medicine.
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
DOI: 10.1111/jvim.12610
Abbreviations:
ADLTE autosomal dominant lateral temporal lobe epilepsy
ADAM a disintegrin and metalloprotease
AED antiepileptic drugs
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
BFJE benign familial juvenile epilepsy
BS Belgian Shepherd
CASPR2 contactin-associated protein 2
CNS central nervous system
EEG electroencephalography
EL mouse epilepsy-like mouse
EPTP epitempin
FBDS faciobrachial dystonic seizures
FEPSO feline complex partial seizure with orofacial
involvement
FLAIR ﬂuid attenuated inversion recovery
FS febrile seizures
FMTLE familial mesial temporal lobe epilepsy
FSEC familial spontaneous epileptic cats
FTLE familial temporal lobe epilepsy
GAD glutamic acid decarboxylase
HS hippocampal sclerosis
IE idiopathic epilepsy





MRI magnetic resonance imaging
NMDA N-methyl-D-aspartate
PET positron emission tomography
PNS peripheral nervous system
PSD postsynaptic density protein
SNP single nucleotide polymorphism
VGKC voltage-gated potassium channel
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channel) and prevents Kv channel inactivation mediated
by the b-subunit of the channel.8 Certain LGI1 mutants
(typically nonsecreted mutants) fail to prevent channel
inactivation,9,10 resulting in more rapidly closing chan-
nels, which extends presynaptic depolarization and leads
to increased calcium inﬂux. Consequently, neurotrans-
mitter release is increased excessively, which may induce
focal seizures. However, because the b-subunit acts
from the intracellular side, it is not clear how secreted
LG1 can modulate the Kv channel.
In the brain, LGI1 also interacts at the presynaptic
membrane with an ADAM (a disintegrin and metallo-
protease) protein family member, the transmembrane
protein ADAM23, and this interaction aﬀects neurite
outgrowth.11,12
LGI1 also is located postsynaptically and co-immu-
noprecipitates with the postsynaptic scaﬀolding protein
PSD-95 (postsynaptic density protein).13 LGI1 does not
interact with PSD-95 directly, but with the extracellular
domain of the transmembrane protein ADAM22.
ADAM22 binds to PSD-95.13 PSD-95 can bind to star-
gazin, which is a transmembrane regulatory subunit of
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR),14 a non-NMDA (N-methyl-D-
aspartate) type glutamate receptor (Fig 1). Incubation
of hippocampal slices with LGI1 leads to an increase in
the synaptic AMPA/NMDA ratio, which can be
explained by the fact that stargazin and PSD95 both
control the number of AMPARs at the synapses, and
both interact indirectly with LGI1 via ADAM22. The
glycosylphophatidylinositol-anchored Nogo receptor 1
(NgR1), whose ligand Nogo inhibits axon outgrowth,
also functions as a receptor for LGI1 and mediates
LGI1-ADAM22 binding.11 The AMPAR-mediated syn-
aptic transmission in the hippocampus is severely
decreased when LGI1 is lacking.12
Binding of LGI1 to ADAM22 and ADAM23 is med-
iated by the EPTP domain of LGI1. ADAM22 or
ADAM23 knockout mice have a strong phenotypical
overlap with LGI1 knockout mice,12,15,16 a phenotype
that is characterized by spontaneous epilepsy and pre-
mature death. Interestingly, LGI1 leads to co-assembly
of ADAM22 and ADAM23. These results suggest that
LGI1 simultaneously binds presynaptic ADAM23 and
postsynaptic ADAM22, pulling both the presynaptic
membrane (containing voltage-gated potassium channel
[VGKC] complexes) and the postsynaptic membrane
(containing AMPA receptor scaﬀolds) together, thus
stabilizing the synapse and increasing neurotransmis-
sion.12 LGI1 also can weakly bind to ADAM11,17
which is an essential protein for proper neuronal func-
tion.
In addition to its roles in synaptic transmission,
LGI1 also has been proposed to regulate neuronal
development. A role for LGI1 has been proposed in the
maturation of glutamatergic synapses.18 Expression of
mutant LGI1 (carrying the mutation 835delC, which is
found in ADLTE and truncates the C-terminal EPTP
domain) in mice arrests normal postnatal change in
postsynaptic NMDA receptor (NMDAR) NR2 subunit
composition, which is an important feature of synapse
maturation. Furthermore, this mutant arrests normal
postnatal down-regulation of presynaptic release proba-
bility, inhibits dendritic pruning and increases spine
density leading to an enhanced excitatory transmis-
sion.18
The proteins LGI2, LGI3, and LGI4 all are neuro-
nally secreted and act on ADAM family members as
does LGI1.5 Although LGI2 acts on the same receptors
as LGI1, LGI2 expression levels are only high in the
immediate postnatal period until halfway through neu-
ral pruning.19 In contrast, LGI1 is highly expressed dur-
ing and after the later pruning phase. Thus, although
both LGI1 and LGI2 seem to have similar roles in syn-
aptic development, they act at diﬀerent time points of
postnatal nervous system development.
LGI3 is located near neuronal plasma membranes in
the brain and colocalizes with endocytosis-associated
proteins (eg, transferrin), exocytosis-associated proteins
(eg, syntaxin-1) and lipid raft markers, such as ﬂotillin-
1, which forms scaﬀolds for membrane microdomains
involved in traﬃcking. LGI3 colocalizes with b-amyloid
in astrocytes, is up-regulated by b-amyloid and pro-
motes additional uptake of b-amyloid. In addition to its
role in endocytosis and exocytosis, LGI3 is involved in
neuronal diﬀerentiation and neuritogenesis.20 Outside of
the brain, LGI3 also is expressed in adipose tissue
and in pre-adipocytes and regulates adipogenesis
through ADAM23.21 In human keratinocytes, LGI3,
Fig 1. Role of LGI1 in synaptic transmission. LGI1 pulls the pre-
synaptic membrane containing VGKC complexes and postsynaptic
membrane together by simultaneous binding to presynaptic
ADAM23 and postsynaptic ADAM22. NR1 promotes binding of
LGI1 to ADAM22. ADAM22 indirectly interacts with AMPA
receptors via PSD-95 and stargazin.
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the secretion of which is stimulated by ultraviolet B
(UVB) irradiation,22 induces cell migration.23 An addi-
tional function of LGI3 in skin is promoting melanin
synthesis.24
LGI4 regulates myelination in the peripheral nervous
system (PNS) and is secreted by Schwann cells. In claw
paw mice, LGI4 is mutated and not secreted, resulting
in a congenital hypomyelinating phenotype.25 Interest-
ingly, ADAM22 also is expressed in Schwann cells,26
and ADAM22-deﬁcient mice have a similar phenotype
with defects in peripheral nerve myelination.16 Binding
of LGI4 to ADAM22 allows LGI4 to regulate PNS
gliogenesis.27
LGI Genes
The LGI gene family originated from 2 to 3 rounds
of gene duplication in early vertebrate development.28
The LGI1 gene was ﬁrst described in a comparison of
neuronal tissue with a glioblastoma cell line (T98G).3
The genes LGI1, 2, 3, and 4 are located on diﬀerent
chromosomes in the human, dog, and cat, and encode
proteins that are secreted by glial and neuronal cells.9
The feline and the canine LGI1 gene products show
100% homology to their human counterpart. The other
members of the LGI family also exhibit interspecies
homologies of 94% to 98% at the protein level. Com-
paring the gene products of the LGI family, they exhi-
bit approximately 40–50% sequence homology with one
another and share functional similarities. Because of the
very similar domain architecture of LGI1 and LGI2,
mutations that are located at the same functional region
aﬀect phenotypically related forms of epilepsy.29 In con-
trast to their highly related architecture, their expression
patterns within the central nervous system (CNS) over-
lap only weakly. In situ hybridization (ISH) with a sin-
gle sagittal section of adult mouse brain identiﬁed low
levels of diﬀuse staining throughout the brain for LGI1,
2, and 3 mRNA, and distinct localizations of intensive
staining (ie, LGI4 mRNA expression was only found in
two areas).9 These ﬁndings were conﬁrmed by a com-
prehensive ISH study that generated a detailed map of
the regional distribution of LGI transcripts in serial
coronal sections.30
LGI and Cancer
The observation of decreased or absent LGI1 expres-
sion in glioblastomas3 led to the hypothesis that LGI1-
knockout animals would develop tumors of neural tis-
sue. However, a study in LGI1/ mice31 demonstrated
only the onset of seizures as early as day 8. Until that
time point, the animals developed similar to their wild-
type or Lgi1+/ littermates, but at the onset of seizures,
they lost weight and died by postnatal day 10–18.
Epileptogenic alterations of the brain were assessed by
immunohistochemistry. Among other epileptic markers,
glial ﬁbrillary acidic protein expression increased with
the number of seizures, mainly in the hilus of the gyrus
dentatus. However, no formation of tumors was found.
The Lgi1+/ littermates behaved similar to the
wild-type mice and reached the same age of >18 months
without tumorigenesis. These animals were comparable
to patients with ADLTE because starting at age 28 days
seizures triggered by auditory stimuli were signiﬁcantly
more frequent than in wild-type animals.
Insertion of LGI1 into a glioblastoma cell line indi-
cated a role of LGI1 in cell-matrix interactions and
migratory processes in the CNS but involvement in glial
tumor suppression could not be substantiated.32 In neu-
ronal and nonneuronal tumor cell lines only infrequent
expression of LGI1–4 mRNA of diﬀering intensity was
detected.33 Also, no correlation was found by compar-
ing their expression in normal tissue and in tumors of
the respective tissues.33 LGI3 had a dose- and time-
dependent protective eﬀect on keratinocytes exposed to
UVB irradiation.22 Furthermore, LGI1 was identiﬁed as
a suppressor that was down-regulated in tumor cells
compared to adjacent normal tissue and additionally
was signiﬁcantly positively correlated with poorer prog-
nosis and metastasis.34–36 These ﬁndings indicate an
important but as yet unidentiﬁed role of the LGI family
in tumorigenesis and demonstrate the potential of LGI1
for suppression of distinct tumors, but deﬁciency (as in
some cases of epilepsy) does not imply the formation of
tumors, especially within the CNS.
Genetic Epilepsy in Humans Caused by LGI1
Mutation
In the International League Against Epilepsy (ILAE)
classiﬁcation of 2010, many familial epilepsies were clas-
siﬁed as electroclinical syndromes and arranged by age
at onset.37 In the adolescence- to adult-onset group,
familial temporal lobe epilepsy (FTLE) was divided into
mesial and lateral forms. The lateral form of FTLE is
known as ADLTE or autosomal dominant partial epi-
lepsy with auditory features (ADPEAF), which is a
benign epileptic syndrome with auditory (main symp-
tom in 64% of patients), visual, olfactory, and other
sensory ictal clinical signs.38–41 These seizures may be
triggered by environmental noises or sounds. Many
patients (90%) show secondary generalized tonic-clonic
seizures. Interictal electroencephalography (EEG) in
patients with ADLTE shows a normal pattern or mild
abnormalities in the temporal region. In most ADLTE
patients, there is no abnormality on conventional mag-
netic resonance imaging (MRI), but recent studies have
found mild abnormalities in the lateral temporal cortex,
and suggested malformation.42,43 Seizures of ADLTE
are eﬀectively treated with conventional antiepileptic
drugs (AEDs) such as carbamazepine, phenytoin, and
valproate.
Approximately 50% of ADLTE families and sporadic
cases of lateral temporal lobe epilepsy with auditory
features have mutations of LGI1.2,44 Over 30 mutations
in LGI1 that result in missense mutations, protein trun-
cation, or internal deletions have been reported.5,10 The
missense mutations tend to be distributed in the 50 half
(LRR) and the truncating mutations preferentially in
the 30 half (EPTP) of the gene. There is no clear corre-
lation between genotypes and phenotypes.
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Other forms of FTLE (eg, mesial form or FMTLE)
have been reported in over 20 families. FMTLE is
divided into FMTLE without hippocampal sclerosis
(HS) or febrile seizures (FS) and FMTLE with HS/
FS.45 FMTLE without HS/FS is characterized by
benign psychic and autonomic auras (deja vu is most
frequent) and complex partial seizures or infrequently
generalizes secondarily.46,47 FMTLE with HS emerges
at approximately 10 years of age with complex partial
seizures (ie, oral or manual automatisms). Various
degrees of HS are found even in asymptomatic family
members, suggesting that the hippocampal abnormali-
ties are inherited although the severity of HS is associ-
ated with seizure severity. These types also are
suggested to be inherited in an autosomal dominant
manner with incomplete penetrance. In FMTLE fami-
lies, LGI1 mutations have not been identiﬁed to date.48
In addition, voltage-gated sodium channel type 2, alpha
subunit (SCN2A) and VGKC mutations were not identi-
ﬁed.49,50 Although some loci are suspected,51–53 a causa-
tive gene has not yet been identiﬁed. Low penetrance,
clinical, or genetic heterogeneity or both may make it
diﬃcult to identify the causative gene.
Genetic Epilepsy in Dogs Associated with LGI
Dysfunction
A genetic cause for epilepsy has been suggested in
many dog breeds, but to date only 2 genes underlying
canine idiopathic epilepsy (IE) have been identiﬁed,
namely LGI2 causing benign familial juvenile epilepsy
(BFJE) in the LR breed,19 and ADAM23 predisposing
to adult-onset epilepsy in the Belgian Shepherd (BS)
breed.54
Childhood epilepsies are common in human medicine,
and the majority of these patients will become seizure-
free by adulthood.55 Until now, only 1 well-deﬁned
juvenile epilepsy syndrome was reported in dogs.56
BFJE in LR dogs is characterized by focal-onset sei-
zures beginning at a mean age of 6.3 weeks and resolv-
ing spontaneously by a mean age of 10 weeks. There is
no sex predilection in the aﬀected dogs. Seizures in
BFJE are characterized by whole-body tremor, ataxia,
and stiﬀness, and are sometimes associated with altered
consciousness. The frequency and severity of seizures
varies among aﬀected individuals. The compound
2-[18F]ﬂuoro-2-deoxy-D-glucose (FDG) is widely used
as a positron emission tomography (PET) tracer in
human patients with epilepsy. A recent FDG-PET study
showed focal cerebrocortical areas of hypometabolism
interictally in dogs with BFJE. A good correspondence
with EEG ﬁndings further supported the suggestion that
the areas of focal parieto-occipitocortical hypometabo-
lism represent the epileptogenic focus in the examined
dogs.57
The disease shows an autosomal recessive inheritance
pattern, and a protein-truncating nonsense mutation in
the LGI2 gene recently has been identiﬁed as a cause of
BFJE.19 In a genetic study, LGI2 mutation also was
screened in 114 dogs with adult-onset epilepsy and in 8
dogs with juvenile epilepsy (40 diﬀerent breeds), but
none was found to carry the BFJE mutation present in
LR dogs.19
Belgian Shepherd dogs suﬀer from a more commonly
reported type of epilepsy. The prevalence of epilepsy
has been estimated to be 9.5% in this breed.58 Epilepsy
in BS dogs is dominated by focal-onset seizures with or
without secondary generalization.54,58 The most com-
monly reported clinical signs of focal seizure phenome-
nology include ataxia, crawling, swaying, fearful
behavior, excessive attention seeking, drooling, and
nausea.54,58,59 In cases with secondary generalization,
focal seizure phenomenology is followed by stiﬀening of
the limbs and neck, muscle fasciculations, tremor, star-
ing, drooling, and tonic-clonic convulsions.54 The mean
age of seizure onset is between 3 and 4 years of
age,54,58,60 and males and females are equally aﬀected.60
A recent study found no signiﬁcant decrease in the life-
span of aﬀected dogs, a remission rate of 13.7% and a
very low frequency of status epilepticus, suggesting that
the epilepsy has a relatively mild course in this breed61
Diﬀerent modes of inheritance for IE in BS dogs
have been suggested from simple Mendelian to poly-
genic inheritance with a recessive gene of major inﬂu-
ence having a substantial inﬂuence. A recent study
found that variants at the ADAM23 locus on CFA37
increase the risk of IE in BS dogs.54 Homozygosity with
respect to 2 separate single nucleotide polymorphisms
(SNPs) within ADAM23 increased the risk for IE
7-fold.54 However, the risk haplotype also is common in
unaﬀected BS, and the actual disease-causing mutation
may lie in the vicinity of the risk locus.54
ADAM23 recently was suggested also to be a poten-
tial major risk gene for IE in other dog breeds.a Muta-
tions in ADAM23 have not been found in epileptic
human patients, but it is a good candidate gene for IE
because ADAM23 interacts with 2 epilepsy-related pro-
teins, LGI1 and LGI2.12,17,19 Furthermore, Adam23
knockout mice exhibit spontaneous seizures, and mice
heterozygous for the Adam23 knockout gene have a
lower seizure threshold.15
Familial Epilepsy in Cats may be Associated with
LGI Dysfunction
Compared with epilepsy in humans and dogs, idio-
pathic epilepsy in cats is less common,62–64 and no
reports identiﬁed genetic epilepsy until recently. In
2010, a familial form of spontaneous epilepsy was
described in cats. So-called ‘familial spontaneous epilep-
tic cats’ (FSECs), were identiﬁed in a closed colony of
laboratory cats.65 From pedigree analysis, the pheno-
type of FSECs is inherited in an autosomal recessive
manner. In addition, inbreeding of FSECs is successful
(ie, it is not a lethal gene), and spontaneous recurrent
seizures, EEG abnormalities, or both occur in F1 kit-
tens. Clinically, FSECs have 2 seizure types: spontane-
ous limbic focal seizures with or without secondary
generalization, and vestibular stimulation-induced gen-
eralized seizures. The former, so-called feline complex
partial seizure with orofacial involvement (FEPSO), is
the common seizure type in epileptic cats, which
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typically consists of attention behavior, arresting or gaz-
ing, lip-smacking, chewing, mydriasis, hypersalivation
and facial twitching, and resembles the limbic kindling
or kainate66 model in cats. The vestibular stimulation-
induced generalized seizures are triggered by stimulation
such as left-to-right swinging or rotating, similar to EL
(epilepsy-like) mice, which is 1 of the genetic models of
temporal lobe epilepsy.67 On scalp and deep EEG with
video monitoring, FSECs show interictal discharges in
the temporal region, and spontaneous clinical and sub-
clinical seizures originating from the unilateral amyg-
dala, hippocampus or both (Fig 2).68 Furthermore,
unilateral hippocampal atrophy without changes in sig-
nal intensity was observed on conventional and volu-
metric MRI (Fig 3).69 All cats with FSECs show their
ﬁrst spontaneous seizure within 2 years of birth, but sei-
zure frequency varies among individuals. Therefore,
FSEC is a true and natural genetic model of temporal
lobe epilepsy, especially FMTLE as mentioned above.
The causative gene of FSEC has not yet been identi-
ﬁed. However, some mutations in the LGI and ADAM
gene families in humans and dogs suggest that these
genes may be associated with the pathophysiology of
FSEC, as well as with limbic encephalitis (LE) in cats
mentioned below.
LGI1-Antibody-Associated Limbic Encephalitis in
Human
Limbic encephalitis is an autoimmune encephalopa-
thy with predominant involvement of the limbic struc-
tures (hippocampus, amygdala, hypothalamus, and
insular and cingulate cortex). LE typically occurs with a
subacute onset and is more frequent in males. Typical
clinical signs in humans are memory impairment,
temporal lobe semiology seizures and psychiatric distur-
bances, and LE often is accompanied by hyponatre-
mia.70 Many patients with LE have a speciﬁc seizure
semiology of faciobrachial dystonic seizures (FBDS),
which usually precede the onset of amnesia, temporal
seizures and confusion,71 and patients do not respond
to AEDs. FBDS are brief (a few seconds in duration),
frequent (median, 50 per day) events that typically
aﬀect the arm and face. On T2/ﬂuid attenuated inver-
sion recovery (FLAIR) MRI, a high signal in the med-
ial temporal lobe found is frequently.
The ﬁrst LE cases described were associated with
malignancies and a poor outcome.72 Antibodies in para-
neoplastic LE are directed against intracellular proteins
(ANNA, antineural nuclear antibody; CV2/CRMP5,
collapsin response mediator protein; PNMA, paraneo-
plastic Ma, named according to the index patient).73,74
These patients have little or no response to immuno-
therapy.75
An important development in the last decade has
been the recognition of immunotherapy-responsive
Fig 2. Intracranial EEG showing an amygdaloid seizure in a FSEC (Male, 7-year old). Focal seizure activity was observed in the left am-
ygdal simultaneously with behavioral restricting and gazing. LAMY, left amygdala; RAMY, right amygdala; LHIP, left hippocampus;
RHIP, right hippocampus; LCOR, eft motor cortex; RCOR, right motor cortex.
Fig 3. T2-weighted MR image in a FSEC (male, 5-year old). The
left hippocampal atrophy (arrow) (also seem like enlargement of
the left lateral ventricle (arrow head)) without abnormal signal
intensity is observed.
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LE.76 The antibodies initially were thought to be
against VGKC.77,78 In LE, however, the antibodies are
only very rarely directed against the VGKCs them-
selves, but are usually directed against other extracellu-
lar or cell surface proteins, which are tightly associated
with VGKCs and have a role in the regulation of neu-
ronal excitability (Fig 4). These proteins are LGI1,
contactin-associated protein 2 (CASPR2) and contactin-
2. Almost all patients with LE79,80 and FBDS81 have
anti-LGI1 antibodies. Faciobrachial dystonic seizures
often precede anti-LGI1 antibody production81.
Evidence also indicates that autoimmune encephalitis
may progress to adult-onset HS and evolve into tempo-
ral lobe epilepsy and immunotherapy often has been
used with success.82 Immunotherapy decreased serum
VGKC-complex antibody concentration and produced
signiﬁcant functional beneﬁts; improvements were great-
est in patients that received steroids early.77 During
immunotherapy, sequential serum antibody concentra-
tions appear to correlate well with the clinical
features77,79 suggesting that the antibodies are causa-
tive.73,83 Indeed, in experiments with mice, application
of anti-LGI1 antibodies to rat hippocampal slices pro-
duced synaptic hyperexcitability, which was mimicked
by alpha-dendrotoxin, a selective blocker of Kv1-
VGKCs.84 These ﬁndings were the ﬁrst evidence that
IgG may decrease VGKC function at CNS synapses
and has a direct eﬀect on channel kinetics. CASPR2
and contactin-2 are expressed in both central and
peripheral nervous system neurons.79 Immunoreactions
against these structures may cause only PNS clinical
signs or only CNS clinical signs or combined clinical
signs as observed in Morvan syndrome.79 Although
LGI1 appears to be the most common antibody associ-
ated with LE, antibodies against glutamic acid decar-
boxylase (GAD),85 the AMPA receptor,86 and the
GABAB receptor also have been associated with this
syndrome.87 In addition, some patients with typical LE,
who have CASPR2 antibodies79 or NMDA receptor
antibodies,83,88 have been identiﬁed.
LGI-Antibody-Associated LE in Cats
Temporal lobe epilepsy is well known from the exper-
imental research in cats,89,90 and there is growing evi-
dence that it also occurs naturally in client-owned cats
worldwide. The condition is characterized by complex
partial seizures with orofacial involvement as well as
FSEC, as mentioned above. Typical ictal clinical signs
include episodic orofacial automatism with salivation,
chewing, licking, facial twitching, motor arrest, vocali-
zation, and mydriasis, referred to as feline complex par-
tial seizure with orofacial involvement (FEPSO).
Behavioral changes also may occur. The etiology is usu-
ally undetermined, but neoplastic and vascular causes
were identiﬁed or suspected in some cases.91–95 In many
cats, acute cluster seizure episodes are observed, resem-
bling LE in humans.91
Very recently, additional investigations showed an
association between FEPSO and antibodies against
VGKC-complexes/LGI1. In a prospective study,
increased concentrations of antibodies directed against
VGK and LGI1 were detected in cats in the acute stage
of the disease. Five of 14 (36%) cats had VGKC anti-
body concentrations above the reference concentration
for positivity (100 pmol/L), whereas no increased anti-
body concentrations could be found in the 19 control
cats, suggesting that the detected immunoglobulins are
associated with the condition. Analysis of sera from
cats in remission showed that the antibody titer had
returned to within the reference range. The study sug-
gests that autoimmune LE might be common in cats,
and that the target of the immunoreaction is the VGKC
complex associated with LGI1. CASPR2 and GAD
antibodies could not be detected.96 Unfortunately, in
this study, EEG and MRI were not performed regularly
and are only available for a single reported cat. The
Fig 4. Scheme how antibody is binding to VGK-complex. The
IgG binds to the complex but in fact to LGI1.
Fig 5. T1-weighted postcontrast MR image of a cat (female,
2 years-old) with seizures and LGI1 antibody-associated limbic
encephlitis. Bilateral contrast enhancement on the hippocampal
region is visible. (arrows are included only unilateral for better
view, but contralateral are the same changes)
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examined cat exhibited temporal lobe seizures, and
MRI showed bilateral temporal lobe changes (Fig 5),
whereas rhythmic positive spike activity with focal onset
was detected by EEG. Increased VGKC-complex anti-
body concentrations also were found.97
Histologically, cats with increased VGKC-complex
antibodies showed lesions in the hippocampus with mild
T-cell inﬁltrates, but strong complement (C9neo) depo-
sition and IgG inﬁltration. In both, human and feline
brains, massive neurodegeneration and acute cell death
predominated. The alterations were accompanied by
mild-to-moderate astrogliosis and activation of microg-
lial cells. In particular, the presence of complement
strongly resembles what is observed in VGKC encepha-
litis in humans and separates FEPSO cats from cats
with other epileptic conditions.98 An additional interest-
ing ﬁnding was that a concurrent neoplasm (pulmonary
adenoma) was found only in 1 cat, suggesting that
paraneoplastic origin is exceptional but may occur. In
other cases, nonparaneoplastic etiology was presumed.
In another post mortem study, 9 of 70 epileptic cats
were found to have LE, but serology was not per-
formed.99
Conclusion
The LGI protein family has many functions, the best
characterized of which is the neuronal function of
LGI1. This protein inﬂuences potassium channel func-
tion, synaptic development of glutamate receptors and
regulates synaptic transmission together with ADAM22
and ADAM23 proteins. Genetic and immune-mediated
dysfunction may cause neuronal hyperexcitability and
lead to epilepsy in laboratory animals, humans, dogs,
and cats. Veterinarians should be aware of the LGI
protein family members and disorders caused by their
dysfunction.
Footnote
a Koskinen LLE, Sepp€al€a EH, Arumilli M, et al Dogs as an Ani-
mal Model for Idiopathic Epilepsy: Identiﬁcation of Common
Risk Variants in the ADAM23 Gene. Conference Proceedings of
European Society of Human Genetics -meeting, Milan, Italy,
2014.
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